Tags

Type your tag names separated by a space and hit enter

Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Drug Test Anal. 2017 Jan; 9(1):30-37.DT

Abstract

Insulin-like growth factor-I (IGF-I) is abused by elite athletes for its metabolic and anabolic effects. We have previously shown that it is possible to detect IGF-I misuse by measuring serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) but a pilot study suggested measuring IGF-II, IGF binding protein-2 (IGFBP-2) and acid-labile subunit (ALS) may improve the detection of IGF-I administration. The aim of the study was to assess this in a randomized controlled trial. Twenty-six female and 30 male recreational athletes were randomized to 28 days' treatment with placebo or recombinant human (rh)IGF-I/rhIGF binding protein-3 (IGFBP-3) complex (30 mg/day or 60 mg/day), followed by 56 days' washout. IGF-II, IGFBP-2 and ALS (women only) were measured using commercial immunoassays. IGFBP-2 increased and IGF-II decreased in response to both low and high dose rhIGF-I/rhIGFBP-3 in both women and men while ALS decreased in women in response to high dose rhIGF-I/rhIGFBP-3. Two days after discontinuing treatment, significant differences remained between the three treatment groups in IGFBP-2 and IGF-II, but not ALS. Thereafter there were no significant differences between the three treatment groups in any of the markers. Combining IGF-I with IGF-II and/or IGFBP-2 improved the performance of the test to detect rhIGF-I/rhIGFBP-3 administration in both women and men. Copyright © 2016 John Wiley & Sons, Ltd.

Authors+Show Affiliations

Human Development and Health Academic Unit, University of Southampton Faculty of Medicine, Southampton, UK. University Hospital Southampton NHS Foundation Trust, Southampton, UK.Human Development and Health Academic Unit, University of Southampton Faculty of Medicine, Southampton, UK. Nuffield Division of Clinical Laboratory Sciences, University of Oxford, UK.Human Development and Health Academic Unit, University of Southampton Faculty of Medicine, Southampton, UK.Department of Pharmacy and Forensic Science, Drug Control Centre, King's College London, UK.Department of Pharmacy and Forensic Science, Drug Control Centre, King's College London, UK.Human Development and Health Academic Unit, University of Southampton Faculty of Medicine, Southampton, UK.Southampton Statistical Sciences Research Institute, University of Southampton, UK.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26888146

Citation

Holt, Richard I G., et al. "Novel Markers to Detect Recombinant Human Insulin-like Growth factor-I (rhIGF-I)/rhIGF Binding Protein-3 (rhIGFBP-3) Misuse in Athletes." Drug Testing and Analysis, vol. 9, no. 1, 2017, pp. 30-37.
Holt RI, Guha N, Böhning W, et al. Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. Drug Test Anal. 2017;9(1):30-37.
Holt, R. I., Guha, N., Böhning, W., Bartlett, C., Cowan, D. A., Sönksen, P. H., & Böhning, D. (2017). Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. Drug Testing and Analysis, 9(1), 30-37. https://doi.org/10.1002/dta.1941
Holt RI, et al. Novel Markers to Detect Recombinant Human Insulin-like Growth factor-I (rhIGF-I)/rhIGF Binding Protein-3 (rhIGFBP-3) Misuse in Athletes. Drug Test Anal. 2017;9(1):30-37. PubMed PMID: 26888146.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. AU - Holt,Richard I G, AU - Guha,Nishan, AU - Böhning,Walailuck, AU - Bartlett,Christiaan, AU - Cowan,David A, AU - Sönksen,Peter H, AU - Böhning,Dankmar, Y1 - 2016/02/17/ PY - 2015/08/30/received PY - 2015/12/02/revised PY - 2015/12/03/accepted PY - 2016/2/19/pubmed PY - 2017/5/17/medline PY - 2016/2/19/entrez KW - IGF-I KW - IGF-II KW - IGFBP-2 KW - biomarker KW - discriminant function SP - 30 EP - 37 JF - Drug testing and analysis JO - Drug Test Anal VL - 9 IS - 1 N2 - Insulin-like growth factor-I (IGF-I) is abused by elite athletes for its metabolic and anabolic effects. We have previously shown that it is possible to detect IGF-I misuse by measuring serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) but a pilot study suggested measuring IGF-II, IGF binding protein-2 (IGFBP-2) and acid-labile subunit (ALS) may improve the detection of IGF-I administration. The aim of the study was to assess this in a randomized controlled trial. Twenty-six female and 30 male recreational athletes were randomized to 28 days' treatment with placebo or recombinant human (rh)IGF-I/rhIGF binding protein-3 (IGFBP-3) complex (30 mg/day or 60 mg/day), followed by 56 days' washout. IGF-II, IGFBP-2 and ALS (women only) were measured using commercial immunoassays. IGFBP-2 increased and IGF-II decreased in response to both low and high dose rhIGF-I/rhIGFBP-3 in both women and men while ALS decreased in women in response to high dose rhIGF-I/rhIGFBP-3. Two days after discontinuing treatment, significant differences remained between the three treatment groups in IGFBP-2 and IGF-II, but not ALS. Thereafter there were no significant differences between the three treatment groups in any of the markers. Combining IGF-I with IGF-II and/or IGFBP-2 improved the performance of the test to detect rhIGF-I/rhIGFBP-3 administration in both women and men. Copyright © 2016 John Wiley & Sons, Ltd. SN - 1942-7611 UR - https://www.unboundmedicine.com/medline/citation/26888146/Novel_markers_to_detect_recombinant_human_insulin_like_growth_factor_I__rhIGF_I_/rhIGF_binding_protein_3__rhIGFBP_3__misuse_in_athletes_ L2 - https://doi.org/10.1002/dta.1941 DB - PRIME DP - Unbound Medicine ER -